- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07825402
A Trial of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P)
The main goal of this clinical trial is to learn if ONO-2808 works to treat adults with the Parkinsonian subtype of Multiple System Atrophy (MSA-P). Researchers will compare ONO-2808 to a placebo (a look-alike substance that contains no drug) to see if ONO-2808 works to treat MSA-P.
Participants will:
- Take ONO-2808 or placebo orally for up to 48 weeks
- Make visits to the clinic for checkups and tests
- Answer questions about their health throughout the trial.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Clinical Team
- Telefonnummer: 888-724-3274
- E-post: clinicaltrials@deciphera.com
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Key Inclusion Criteria:
- Participants with a diagnosis of clinically established or clinically probable MSA-P according to the 2022 Movement Disorder Society (MDS) criteria for MSA diagnosis.
Participants in the early stages of the disease, defined as a maximum of 5 years since the onset of one of the following symptoms associated with MSA-P:
- Parkinsonism
- Orthostatic hypotension
- Urinary dysautonomia
- Participants with an anticipated survival of at least 3 years in the opinion of the Investigator.
- Participants who are able to ambulate without the assistance of another person, defined as the ability to take at least 10 steps and then to turn around and walk at least another 10 steps. Use of assistive devices (eg, walker or cane) is allowed.
- Ability to swallow oral medication and willingness to adhere to the study drug regimen.
- Normal range of laboratory values at screening and baseline, especially liver function tests.
- Participants receiving treatment (including chronic medications, and herbal or dietary supplements) for symptoms associated with MSA must be on a stable dosage for at least 60 days prior to randomization based on the judgment of the Investigator. Participants must not initiate new treatment within 60 days prior to randomization.
Key Exclusion Criteria:
- Participants with the cerebellar subtype of MSA according to the 2022 MDS criteria for MSA diagnosis.
- Female participants who are pregnant, planning to become pregnant during the study, or breastfeeding.
- Participants with a clinically significant or unstable medical or surgical condition other than MSA-P that, in the opinion of the Investigator, might preclude safe completion of the study or might affect the results of the study (eg, pulmonary, cardiovascular [including bradyarrhythmia], macular edema, and significant renal or hepatic dysfunction).
- Neurological diseases/disorders other than MSA-P, such as Parkinson's disease, dementia with Lewy bodies, essential tremor, progressive supranuclear palsy, spinocerebellar ataxia, spastic paraparesis, corticobasal degeneration, or vascular, normal pressure hydrocephalus, pharmacological, or postencephalitic parkinsonism.
- Any abnormalities, other than MSA, found on the centrally read brain MRI that, in the opinion of the Investigator, may constitute a confounder for the study or preclude safe participation.
- Participants with documented liver diseases, cirrhosis, prior drug-induced liver injury (DILI), or ascites or symptoms and signs of encephalopathy due to hepatic dysfunction.
Other protocol-defined inclusion and exclusion criteria apply.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Placebo-jämförare: Placebo
|
Matching placebo will be administered to participants orally once daily for 48 weeks.
|
|
Experimentell: ONO-2808 Low Dose
|
ONO-2808 will be administered to participants orally once daily for 48 weeks.
|
|
Experimentell: ONO-2808 High Dose
|
ONO-2808 will be administered to participants orally once daily for 48 weeks.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Change from Baseline in modified United Multiple System Atrophy Rating Scale (mUMSARS) Part I (excluding Item 11) with Collapsed Scoring (0-3)
Tidsram: Baseline, Week 48
|
Baseline, Week 48
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Change from Baseline in Multiple System Atrophy Quality of Life Scale (MSA-QoL) Motor Subscale Score
Tidsram: Baseline, Week 48
|
Baseline, Week 48
|
|
Change from Baseline in Magnetic Resonance Imaging (MRI) Volumetric Assessments
Tidsram: Baseline, Week 48
|
Baseline, Week 48
|
|
Change from Baseline in Total United Multiple System Atrophy Rating Scale (UMSARS) Score (Part I and Part II, all items)
Tidsram: Baseline, Week 48
|
Baseline, Week 48
|
|
Change from Baseline in mUMSARS Score
Tidsram: Baseline, Week 48
|
Baseline, Week 48
|
|
Change from Baseline in MSA-QoL Total Score
Tidsram: Baseline, Week 48
|
Baseline, Week 48
|
|
Change from Baseline in Patient Global Impression of Change (PGI-C) Score
Tidsram: Baseline, Week 48
|
Baseline, Week 48
|
|
Change from Baseline in Patient Global Impression of Severity (PGI-S) Score
Tidsram: Baseline, Week 48
|
Baseline, Week 48
|
|
Change from Baseline in Clinical Global Impression of Change (CGI-C) Score
Tidsram: Baseline, Week 48
|
Baseline, Week 48
|
|
Change from Baseline in Clinical Global Impression of Severity (CGI-S) Score
Tidsram: Baseline, Week 48
|
Baseline, Week 48
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Studierektor: Clinical Team, Ono Pharmaceutical Co., Ltd.
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- ONO-2808-03-001
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .